metoject 20 mg injektionsvätska, lösning i förfylld injektionspenna
medac gesellschaft für klinische spezialpräparate mbh - metotrexat - injektionsvätska, lösning i förfylld injektionspenna - 20 mg - metotrexat 20 mg aktiv substans
metoject 10 mg injektionsvätska, lösning i förfylld injektionspenna
medac gesellschaft für klinische spezialpräparate mbh - metotrexat - injektionsvätska, lösning i förfylld injektionspenna - 10 mg - metotrexat 10 mg aktiv substans
metotrexat astron 50 mg/ml injektionsvätska, lösning i förfylld spruta
astron research ltd - metotrexat - injektionsvätska, lösning i förfylld spruta - 50 mg/ml - metotrexat 50 mg aktiv substans
namaxir 10 mg injektionsvätska, lösning i förfylld spruta
teva b.v. - metotrexat - injektionsvätska, lösning i förfylld spruta - 10 mg - metotrexat 10 mg aktiv substans
namaxir 2,5 mg injektionsvätska, lösning i förfylld spruta
teva b.v. - metotrexat - injektionsvätska, lösning i förfylld spruta - 2,5 mg - metotrexat 2,5 mg aktiv substans
namaxir 7,5 mg injektionsvätska, lösning i förfylld spruta
teva b.v. - metotrexat - injektionsvätska, lösning i förfylld spruta - 7,5 mg - metotrexat 7,5 mg aktiv substans
yanulez 2 mg/0,03 mg filmdragerad tablett
heaton k.s. - dienogest; etinylestradiol - filmdragerad tablett - 2 mg/0,03 mg - laktosmonohydrat hjälpämne; etinylestradiol 30 mikrog aktiv substans; dienogest 2 mg aktiv substans
lenalidomide krka d.d. novo mesto (previously lenalidomide krka)
krka, d.d., novo mesto - lenalidomide hydrochloride monohydrate - multiple myeloma; lymphoma, follicular - immunsuppressiva - multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) är indicerat för behandling av vuxna patienter med tidigare obehandlat multipelt myelom som inte är berättigade till transplantation. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) är indicerat för behandling av vuxna patienter med tidigare obehandlat multipelt myelom som inte är berättigade till transplantation. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).
lenalidomide krka (previously lenalidomide krka d.d. novo mesto)
krka, d.d., novo mesto - lenalidomide hydrochloride monohydrate - multiple myeloma; myelodysplastic syndromes; lymphoma, follicular; lymphoma, mantle-cell - immunsuppressiva - multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) är indicerat för behandling av vuxna patienter med tidigare obehandlat multipelt myelom som inte är berättigade till transplantation. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 och 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) är indicerat för behandling av vuxna patienter med tidigare obehandlat multipelt myelom som inte är berättigade till transplantation. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 och 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).
methotrexate accord 25 mg injektionsvätska, lösning i förfylld injektor
accord healthcare b.v. - metotrexat - injektionsvätska, lösning i förfylld injektor - 25 mg - metotrexat 25 mg aktiv substans